Introduction
Community-acquired pneumonia (CAP) is still a common source of morbidity and mortality worldwide, and places heavy burdens on healthcare services. [1] [2] [3] Although the high death rate seen before the advent of antibiotics has fallen, the disease can still be fatal, especially in the very young and the elderly. Empirical therapy is generally used while the results of bacteriological tests are awaited. Although Streptococcus pneumoniae is still generally the predominant pathogen, the importance of other organisms, many of which are resistant to -lactams, has increased. In particular, organisms responsible for atypical pneumonia, including Legionella pneumophila, Chlamydia spp. and Mycoplasma pneumoniae, play an important role. 2 Macrolide antibiotics have been used for over 30 years for treating a wide range of infections, including pneumonia caused by atypical pathogens. Roxithromycin was the first of a new generation of macrolides with an antimicrobial spectrum similar to that of erythromycin 4 but with a better pharmacokinetic profile. 5 The serum concentrations achieved for roxithromycin are up to three times greater than those for erythromycin 6 and roxithromycin penetrates well into tissues, including those of the respiratory tract. 7, 8 Its elimination half-life (12 h) makes it suitable for once-or twice-daily dosing, thereby improving compliance. It is generally well tolerated, with fewer gastrointestinal side-effects than erythromycin. 5 This study compares the effect of once-daily dosing with either roxithromycin or cefixime in adult patients with CAP in three outpatient clinics in Argentina. Cefixime is an orally administered, third-generation cephalosporin with good activity against Gram-positive and -negative bacteria and a high resistance to -lactamases. It is suitable for once-daily administration and has become widely used
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Comparison of roxithromycin with cefixime in the treatment of adults with community-acquired pneumonia This study compared the efficacy and tolerability of once-daily dosing with either roxithromycin or cefixime in previously healthy adult patients aged between 18 and 60 with markers of uncomplicated community-acquired pneumonia (CAP) in three outpatient clinics in an open, randomized study. Sixty patients were enrolled: 17 males and 13 females received roxithromycin 300 mg once daily for 8-10 days and 22 males and eight females received 400 mg cefixime once daily for the same period. All patients were assessed clinically, radiologically and bacteriologically before inclusion, immediately after the study and approximately 1 month later. The most common pathogen isolated from sputum was Streptococcus pneumoniae (in 26 (43%) of 60 patients), with mixed organisms isolated from the sputum of 18 (30%) of 60 patients. Staphylococcus aureus, Haemophilus influenzae or Moraxella catarrhalis occurred in 11/60 patients, and atypical pathogens were detected by serology in 7/26 cases in the roxithromycin group and 3/23 in the cefixime group. The severity of infection was rated as mild to moderate at the beginning of the trial. At the end of the study treatment period, clinical cure rates were 30/30 (100%) for roxithromycin and 28/30 (94%) for cefixime, with one patient on cefixime being classed as a partial responder and one patient being classed as a failure and withdrawn. However, radiological abnormalities persisted in three patients on roxithromycin and one on cefixime. Of the 59 patients who completed the study, none required further antibiotic therapy. No abnormal laboratory parameters or adverse events were reported in either group. Roxithromycin at a daily dose of 300 mg was an effective and well-tolerated treatment for the empirical treatment of mild to moderate CAP in this group of patients.
in the treatment of CAP in Argentina, even though it has limited activity against non-bacterial pathogens.
Materials and methods

Patients
Sixty outpatients aged between 18 and 60 years with clinical symptoms of uncomplicated CAP were recruited into the study at three centres in Argentina. Both male and female patients were recruited provided they gave written informed consent and met all selection criteria. Patients had to be previously healthy, and to have clinical signs and symptoms and radiological evidence of acute, uncomplicated pneumonia.
Exclusion criteria
Patients were excluded from the study if they had clinical signs and symptoms compatible with cardiac (i.e. dyspnoea of cardiac origin, oedema, cyanosis), renal (i.e. oliguria, anuria) or hepatic (i.e. jaundice, ascites, hepatic encephalopathy) insufficiency and/or laboratory abnormalities compatible with impaired hepatic function (transaminases more than three times the upper limit of the normal value, or a prothrombin time Ͻ 50% of the normal value, or a serum bilirubin concentration of (Ͼ30 mg/L) or impaired renal function (creatinine (Ͼ20 mg/L and/or creatinine clearance Ͻ50 mL/min), rapidly progressive disease, major psychiatric disease or chronic bronchitis. Patients who were taking probenecid or any other drugs that could affect the metabolism of the test compounds, or ergotamine-type alkaloids for migraine, or who had taken antibiotics during the week preceding study inclusion or any other experimental therapy in the 15 days preceding inclusion were also excluded. Pregnant and nursing women, and patients with a history of alcohol abuse or hypersensitivity to macrolides or cephalosporins were excluded.
Study conduct
Clinical, radiological, laboratory and bacteriological parameters for the diagnosis of CAP were determined before the start of the study. CAP was diagnosed from medical history, physical examination and chest radiography. The following clinical signs and symptoms were evaluated at inclusion: fever, cough, chest pain, sputum production, sputum purulence and clinical signs compatible with pneumonia. A chest X-ray was performed; segmental or lobar consolidation, with or without an air bronchogram, was considered indicative of pneumonia. Patients were included only if both clinical and radiological evidence of pneumonia was obtained. The severity of infection was rated as mild, moderate or severe (severe infections requiring hospitalization were excluded) and the patient's general condition evaluated as good, fair or poor. Clinical examinations were performed before the start of treatment, at day 3 or 4, at the end of treatment and again at 30-40 days after treatment. Patients began medication before the bacteriological results were available.
Treatment
Patients who entered the study were assigned on a randomized, open basis to receive either 300 mg of roxithromycin or 400 mg of cefixime each to be taken in the morning for a minimum of 8 days and for a maximum of 10 days. No other antibiotics were allowed and all concomitant medications were recorded. Patients excluded from the study could be replaced by a new patient who would receive the same medication as the excluded patient according to the monitor's code.
The study was an open, centrally randomized 1:1 parallel study. Central randomization was based on balanced blocks of six treatments. When a patient was eligible for the study, the investigator called the monitor. The monitor was responsible for allocating patients to a particular treatment. To do this, he opened an envelope corresponding to the patient number allocated chronologically to this centre and confirmed treatment. Another set of randomization envelopes remained closed at the Central Randomisation Site until the end of the study. At the end of the study, this second set of envelopes was opened to verify that the randomization process had been followed properly. No randomization errors occurred. Ten blocks were completed and all patients were included in chronological order within each block.
A repeat chest X-ray was optional during therapy but mandatory within 48 h after stopping treatment. Further X-rays were taken if the radiograph was still abnormal after completing treatment. Routine haematological and biochemical tests were performed before treatment and within 48 h of stopping treatment. If possible, sputum samples were taken at inclusion to isolate, identify and test the susceptibility of the causal pathogen, sputum samples obtained 48 h before randomization being considered valid as 'pre-treatment culture'. The sputum sample was considered suitable if Ͻ10 epithelial cells and Ͼ25 PMN were observed per high-power field in a direct examination. After direct examination, suitable sputum was cultured. The following methods of isolating pathogens were also allowed: trans-tracheal puncture, protected brush or any other technique considered to be appropriate (e.g. aspiration of pleural effusion or open lung biopsy). The pathogen was considered responsible for the pneumonia if it was isolated by any of these techniques. Cultures were repeated 48 h after the end of treatment, whenever material for culture was available. A blood sample was taken for serology to detect M. pneumoniae (haemagglutination technique) and chlamydiae (complement fixation test and indirect immunofluorescence). The sensitivity of the microorganisms isolated was determined using a standard disc method. Sensitivity criteria for roxithromycin were zone diameters of Ͻ17 mm (resistant) and Ͼ22 mm (susceptible). The corresponding values for cefixime were Ͻ15 mm (resistant) and Ͼ19 mm (susceptible). Patients with isolates that were known to be resistant to either of the study drugs before the start of treatment were withdrawn from the study. If the isolated pathogen was resistant but the patient's clinical condition was improving, the patient could stay in the study at the discretion of the investigation. In that case the patient was evaluable clinically but not from the bacteriological point of view.
All concomitant illnesses and adverse events were recorded. At the end of the study each patient was evaluated for both clinical and bacteriological response to treatment and tolerance of medication.
Evaluation
To be evaluable, patients had to meet all inclusion/ exclusion criteria, to have taken no other antibiotic therapy pre-or post-treatment, to have taken the study medication for at least 5 days (except in cases of failure) and not to have missed more than 1 day of medication. Clinical responses were classified as cure, partial response or failure. 'Cure' was defined as a complete resolution of all signs and symptoms of pneumonia, plus improvement of radiological findings. 'Partial response' was defined as an improvement in one or more symptoms without a complete resolution of the infection, plus a chest radiograph showing no progression of disease. 'Failure' was defined as either persistence of clinical signs and symptoms, appearance of new clinical signs compatible with active infection, progression of radiological findings, or death from pneumonia.
Bacteriological responses were classified as cure or failure. 'Bacterial cure' was defined as the eradication of the pathogen(s), or eradication of the causal pathogen which was replaced by a new pathogen but with no evidence of a new infection, or a clinical cure with no posttherapy culture obtained. 'Bacteriological failure' was defined as a persistence of the causal pathogen, or the eradication of the causal pathogen but with a new clinically significant pathogen emerging, or only a partial eradication of multiple causal pathogens.
Statistical analysis
Age, weight and height were analysed by Student's t-test, while gender, severity of infection and patients' general status were analysed using a 2 test with Yates' correction. Serological results were analysed by Fisher's test. Clinical signs and symptoms (fever, heart rate, respiratory rate, systolic and diastolic blood pressure) were analysed with ANOVA with a posterior Dunnett test, taking into account the admission values, the values during treatment and the values at end of treatment.
Ethics Committee
The study protocol was evaluated and approved by the Ethics Committee from 'Clinica del Torax' in Rosario.
Results
Sixty patients were included in the trial, and randomized to two groups, 30 to receive roxithromycin and 30 to receive cefixime. Of these 60 patients, 59 finished treatment. There were 17 males and 13 females in the roxithromycin group and 22 males and eight females in the cefixime group. There were no statistical differences in the demographics of the two groups (Table I) . The infections were all classified as mild or moderate at the start of the trial, and the patients' condition as good or fair (Table I) . Seventeen patients had concurrent illnesses or aggravating factors (mostly secondary to smoking) at the beginning of the study.
Pathogens isolated at the start of treatment are shown in detail in Table II . In both groups the major pathogen isolated was S. pneumoniae, although many patients had a polymicrobial flora. There were three isolates of Gramnegative bacilli; two of these were Klebsiella pneumoniae (both susceptible to roxithromycin and cefixime) and one Pseudomonas aeruginosa. In addition, serology was positive for seven patients in the roxithromycin group (two cases of Chlamydia psittaci and five of M. pneumoniae) and three in the cefixime group, all of whom had evidence of infection with M. pneumoniae. Where sensitivity tests were performed on pre-treatment isolates, all were sensitive to roxithromycin, but the isolate of P. aeruginosa was resistant to cefixime.
The clinical signs and symptoms of the disease before treatment included elevated respiratory rates and temperatures, chest pain and expectoration. These improved significantly (as judged by Fisher's exact test) after treatment, with temperatures and respiratory rates returning to normal (Table III) . All 30 (100%) patients who received roxithromycin completed the study and were evaluated by the investigators as clinically cured, as opposed to 28 (94%) of 30 in the cefixime group (Figure,  panel a) . One patient in the cefixime group was evaluated as a partial responder and one patient failed. For the patient with partial clinical response it was not possible to determine a responsible pathogen, as the results from sputum culture revealed a polymicrobial flora and serological tests were negative. The patient classed as a failure had P. aeruginosa isolated from the sputum, and this did not respond clinically or bacteriologically to treatment. The cefixime treatment was discontinued and replaced with a quinolone plus aminoglycoside, which resulted in a cure. At the end of treatment, chest radiographs still showed abnormalities in three of the 30 patients in the roxithromycin group and one of the 29 patients in the cefixime group, but none of these patients required further antibiotic treatment.
In the roxithromycin group bacteriological response was judged satisfactory as a result of clinical cure only (no material was available at the post-treatment visit) in 17 patients (57%), while two patients (6%) had a satisfactory bacteriological response, with colonization at the posttreatment visit. The bacteriological response was considered unassessable in 11 patients (37%): ten patients had polymicrobial flora at inclusion and one patient could not expectorate any sputum at inclusion.
In the cefixime group, bacteriological response was judged satisfactory as a result of clinical cure in 16 of 30 patients (53%), while four patients (13%) had a satisfactory bacteriological response, with colonization at the post-treatment visit. There was one bacteriological failure (the patient from whom P. aeruginosa was isolated) and nine (30%) unassessable patients (eight who had polymicrobial flora at inclusion and one without sputum at inclusion).
Tolerance of the antibiotics was good in both groups, with no adverse events reported. No abnormalities were 
Discussion
Figures for the incidence of the various pathogens in CAP are not easy to obtain and are highly dependent upon the methods used, the time of the year, and the type of population sampled. 9, 10 Although most surveys still find that S. pneumoniae and H. influenzae are the predominant pathogens, 2,9-11 other organisms such as M. catarrhalis,
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Legionella pneumophila, Chlamydia spp. and M. pneumoniae are reported with varying frequencies. The inability to grow Chlamydia spp. and M. pneumoniae, and to a lesser extent, L. pneumophila, on ordinary laboratory media can hamper their recognition as pathogens and had led to an underestimate of their importance. Thom et al. 13 found a surprisingly high incidence of these organisms in a survey of over 600 students, as did Karalus et al. 14 and our small study confirms the importance of atypical pathogens, which were responsible for ten (17%) of the 60 cases of CAP.
The macrolide erythromycin, by virtue of its broad spectrum of activity against both the traditional major pathogens and atypical pathogens, has become a mainstay of treatment for CAP. Unfortunately, it is poorly and erratically absorbed from the gastrointestinal tract, has a relatively short half-life and has a high rate of gastrointestinal side-effects, limiting patient compliance. The superior pharmacokinetic profile of roxithromycin, 15, 16 including penetration into tissues of the respiratory tract, 7,8 a pronounced post-antibiotic effect against respiratory pathogens in vitro 17 as well as proven efficacy in lower respiratory tract infections 18 make it an attracive agent in treating these infections. Furthermore, it is more active than clarithromycin or azithromycin against S. pneumoniae, which remains the principal pathogen in CAP.
In our study of uncomplicated CAP, both roxithromycin and cefixime showed excellent clinical efficacy and tolerance when administered once daily. All 30 of the patients treated with roxithromycin and 28 of the 30 given cefixime were cured. One patient in the cefixime group had a partial response, and one patient who had a P. aeruginosa infection failed treatment. The most commonly isolated pathogen was S. pneumoniae, found in 26/60 (43%) of the patients. A mixed infection was found in 18 patients, and 11 were infected with S. aureus, H. influenzae or M. catarrhalis. There were ten cases of M. pneumoniae or C. psittaci infection. The favourable clinical response of M. pneumoniae infection to cefixime in three patients was unexpected since -lactams are ineffective in vitro against these pathogens. This presumably reflects the mild, selflimiting nature of many of these infections.
This study shows that roxithromycin, a macrolide with a long half-life and good tissue penetration, gave 100% clinical cure in 30 mild to moderate cases of CAP. The compound was well tolerated, producing no side-effects. Roxithromycin is a safe and effective alternative to ␤-lactam antibiotics in the treatment of mild or moderate CAP. 
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